Use an inotrope only when low cardiac output causes hypoperfusion despite adequate filling and MAP. Dobutamine is the usual first choice; milrinone or levosimendan suit beta-blocked or RV-failure patients.
At the bedside
Timed steps- 1
Low output is the problem
ConfirmEcho: poor LV or RV function, low LVOT VTI (< 15 cm suggests low stroke volume), cold periphery, low ScvO2 (< 65-70%), raised lactate with adequate MAP and filling.
- 2
MAP first
PrepareInotropes vasodilate: secure MAP ≥ 65 with noradrenaline before or with the inotrope.
- 3
Dobutamine
Start2.5 mcg/kg/min, increase every 10-15 min by 2.5 to 5-10 mcg/kg/min.
- 4
Milrinone or levosimendan
AlternativesBeta-blocked patient, pulmonary hypertension or RV failure: milrinone 0.125-0.5 mcg/kg/min (no bolus); levosimendan 0.05-0.2 mcg/kg/min for 24 h.
- 5
Response
MonitorLactate, ScvO2, urine output, VTI/CO, arrhythmias. Stop if tachyarrhythmia or no improvement in 1-2 h.
- 6
Early
WeanInotropes increase myocardial O2 use and arrhythmias: use the lowest effective dose for the shortest time.
First-line inotrope
Dobutamine
- Dose
- 2.5-10 mcg/kg/min (max 20)
- Range
- 2.5–20 mcg/kg/min
- Preparation
- 250 mg in 50 mL = 5000 mcg/mL
- Worked example
- 60 kg × 5 mcg/kg/min = 300 mcg/min × 60 = 18 000 mcg/h ÷ 5000 = 3.6 mL/h
Inodilator (RV failure, high PVR, beta-blocked)
Milrinone
- Dose
- 0.125-0.5 mcg/kg/min (max 0.75); omit bolus
- Range
- 0.125–0.75 mcg/kg/min
- Preparation
- 10 mg in 50 mL = 200 mcg/mL
- Worked example
- 70 kg × 0.25 = 17.5 mcg/min × 60 = 1050 mcg/h ÷ 200 = 5.25 mL/h
Halve or reduce dose in AKI.
Open infusion calculatorInodilator (beta-blocked, decompensated HF)
Levosimendan
- Dose
- 0.05-0.2 mcg/kg/min; no bolus if SBP < 100
- Preparation
- 12.5 mg in 500 mL D5 = 25 mcg/mL
- Worked example
- 70 kg × 0.1 = 7 mcg/min × 60 = 420 mcg/h ÷ 25 = 16.8 mL/h
Calculators for this topic
References
- 1
- 2
- 3
Choosing an inotrope
Step 1 of ~4
Decision: MAP ≥ 65 mmHg?
Based on McDonagh TA, Metra M, Adamo M, et al. Educational use; follow local protocol.
Evidence
- ESC HF 2021: inotropes may be considered in patients with hypotension (SBP < 90) and hypoperfusion despite adequate filling; not recommended routinely because of safety concerns.
- DOREMI (2021): milrinone vs dobutamine in cardiogenic shock had no difference in the composite outcome.
Controversies
- No inotrope has shown a mortality benefit. Levosimendan did not help septic shock (LeoPARDS) or cardiac surgery outcomes.
🇮🇳 India notes
- Dobutamine is cheap and widely available; milrinone and levosimendan are more expensive and sometimes stocked only in cardiac centres.
References
- 1
- 2
- 3
Test yourself
Module quiz · score 70% to complete the module
Educational reference for trained clinicians. Check doses against your hospital protocol and the patient in front of you.

